Cephamycins: a review, prospects and some original observations.
The cephamycins are a group with great potential. The first member of the group intended for therapeutic use offers the following advantages over existing cephalosporins: 1. Stability to various beta-lactamases; in an environment increasingly threatened by R-factors, this property may be of increasing value as time passes. 2. Possible lack of cross-allergenicity with other beta-lactam antibiotics. 3. Activity against anaerobic strains. Cefoxitin is only the first semi-synthetic derivative; presumably there are other compounds awaiting assessment which have even more favourable properties.
D000818:Animals; D002440:Cefoxitin / Q000494:pharmacology; D002510:Cephalosporinase / Q000494:pharmacology; D002511:Cephalosporins; D002512:Cephalothin / Q000494:pharmacology; D002513:Cephamycins; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D006868:Hydrolysis; D051379:Mice; D013302:Streptomyces / Q000378:metabolism
D002511:Cephalosporins; D002513:Cephamycins; D002440:Cefoxitin; D002510:Cephalosporinase; D002512:Cephalothin